Korsana Biosciences Inc KRSA

$37.56 +2.11 (5.95%)

Valuation

Market cap
1,614,429,000
Revenue TTM
$2,070,000
Net income TTM
$-3,530,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-170.53%
Debt to equity
0.00

Trading

Volume
265,200
Avg volume
145,392
Day's range
$34.08 – $39.41
Shares out
45,541,000
Stochastic %K
80%
Beta
1.85
Analysts
Strong Buy
Price target
$52.00

Price

Company profile

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company...

Show more

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 516 2325
Website
https://korsana.com
Address
221 Crescent Street, Building 23 Suite 105, Waltham, United States

Latest news

No headlines yet.